Want to see HK:6996 full AI Analyst Report?
Top Page
Antengene Corporation Limited
(6996)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$2.50
▼(-52.56% Downside)
Action:Reiterated
Date:10/04/26
The score is driven primarily by financial performance: revenue growth and narrowing losses/cash burn are positives, but the company remains loss-making with negative free cash flow. Technical indicators add pressure due to a clear downtrend and negative momentum. Valuation is only modestly supportive given a relatively high P/E and no dividend yield.
Positive Factors
Revenue Growth
The return to meaningful annual revenue growth indicates improving commercial traction and a larger base from which to scale. If sustained, stronger product or collaboration revenue can support broader market reach and provide operating leverage as the pipeline develops.
Negative Factors
Persistent Net Losses
Deep operating and net losses show that current revenue is not yet sufficient to cover the costs of research, development, and commercialization. Persistent unprofitability may require continued external funding and delays the point at which the business can compound value independently.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The return to meaningful annual revenue growth indicates improving commercial traction and a larger base from which to scale. If sustained, stronger product or collaboration revenue can support broader market reach and provide operating leverage as the pipeline develops.
Read all positive factors
Antengene Corporation Limited (6996) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.80B
Dividend YieldN/A
Average Volume (3M)813.89K
Price to Earnings (P/E)29.6
Beta (1Y)2.25
Revenue Growth605.95%
EPS GrowthN/A
CountryHK
Employees122
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.08
Shares Outstanding689,536,600
10 Day Avg. Volume849,719
30 Day Avg. Volume813,893
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.32
Price to Sales (P/S)20.24
P/FCF Ratio-11.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.00Price Target Upside89.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.43
Revenue Forecast (FY)HK$845.17M
Antengene Corporation Limited Business Overview & Revenue Model
Company Description
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-...
How the Company Makes Money
Antengene’s revenue model is primarily driven by (1) commercialization of approved products in markets where it has launched or obtained marketing authorizations, and (2) collaboration and out-licensing arrangements related to its drug candidates....
Antengene Corporation Limited Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
36
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 558.15M | 105.34M | 91.95M | 67.31M | 160.13M | 28.77M |
| Gross Profit | 510.54M | 86.83M | 74.17M | 55.01M | 132.00M | 24.19M |
| EBITDA | 173.08M | -214.96M | -337.84M | -550.31M | -851.73M | -606.75M |
| Net Income | 50.61M | -239.13M | -319.25M | -581.18M | -601.49M | -655.53M |
Balance Sheet | ||||||
| Total Assets | 1.52B | 1.26B | 1.34B | 1.62B | 2.14B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 764.90M | 734.29M | 900.24M | 1.19B | 1.79B | 2.37B |
| Total Debt | 257.88M | 257.51M | 249.44M | 201.02M | 57.95M | 14.81M |
| Total Liabilities | 605.88M | 614.86M | 493.93M | 471.20M | 428.84M | 163.29M |
| Stockholders Equity | 912.14M | 642.70M | 850.80M | 1.15B | 1.71B | 2.39B |
Cash Flow | ||||||
| Free Cash Flow | -130.28M | -178.86M | -382.57M | -778.87M | -665.56M | -581.04M |
| Operating Cash Flow | -72.82M | -127.51M | -321.96M | -665.77M | -572.18M | -557.65M |
| Investing Cash Flow | -111.55M | 116.16M | 345.24M | 587.07M | -208.16M | -103.88M |
| Financing Cash Flow | 14.28M | -3.19M | 45.17M | 131.84M | -20.73M | -81.29M |
Antengene Corporation Limited Technical Analysis
Negative
5.27
Price Trends
3.37
Negative
3.65
Negative
3.98
Negative
Market Momentum
-0.17
Positive
34.12
Neutral
25.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6996, the sentiment is Negative. The current price of 5.27 is above the 20-day moving average (MA) of 3.06, above the 50-day MA of 3.37, and above the 200-day MA of 3.98, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 34.12 is Neutral, neither overbought nor oversold. The STOCH value of 25.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6996.
Antengene Corporation Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
44 Neutral | HK$1.80B | 29.59 | 6.51% | ― | 605.95% | ― | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% | |
41 Neutral | HK$7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
* Healthcare Sector Average
HK:6996
Antengene Corporation Limited
2.79
-2.33
-45.51%
HK:1801
Innovent Biologics
79.75
-10.45
-11.59%
HK:9966
Alphamab Oncology
6.22
-5.47
-46.79%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.44
-42.85%
HK:2616
CStone Pharmaceuticals
4.94
-1.28
-20.58%
HK:6855
Ascentage Pharma Group International
27.20
-40.70
-59.94%
Antengene Corporation Limited Corporate Events
Antengene Grants 11.52 Million RSUs Under 2022 Incentive Scheme
Sep 10, 2026
Antengene Corporation Limited has granted 11,520,000 restricted share units under its 2022 RSU Scheme to 75 eligible participants, including employees, senior management, executive directors and independent non-executive directors. The RSUs, with ...
Antengene Wins Australian Approval to Begin Phase I Trial of Autoimmune Drug ATG-201
Aug 24, 2026
Antengene Corporation Limited has secured Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration for its Phase I ATTRACT study. The trial will evaluate ...
Antengene Swings to Interim Profit on Licensing-Driven Revenue Surge
Aug 21, 2026
Antengene Corporation Limited reported a sharp turnaround in its interim results for the six months ended June 30, 2026, driven by a surge in revenue from licensing and collaboration deals. Revenue jumped to RMB513.1 million from RMB53.2 million a...
Antengene Sets Board Meeting to Approve 2026 Interim Results
Aug 10, 2026
Antengene Corporation Limited has scheduled a board meeting for August 21, 2026 to review and approve the interim results for the six months ended June 30, 2026 and to authorize their publication. The announcement signals upcoming disclosure of th...
Antengene Updates Board Composition and Committee Roles
Aug 3, 2026
Antengene Corporation Limited announced the current composition of its board of directors, led by Chairman and Chief Executive Officer Dr. Jay Mei and executive director Dr. Bing Hou, alongside three independent non-executive directors. The compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.